Zacks Research Issues Negative Forecast for BIO Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Equities research analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a report released on Monday, June 9th. Zacks Research analyst R. Department now expects that the medical research company will post earnings of $2.03 per share for the quarter, down from their prior forecast of $2.14. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q3 2025 earnings at $2.20 EPS, Q4 2025 earnings at $2.60 EPS, FY2025 earnings at $9.37 EPS, Q1 2026 earnings at $2.80 EPS, Q2 2026 earnings at $2.45 EPS, Q3 2026 earnings at $2.64 EPS, Q4 2026 earnings at $2.94 EPS and FY2026 earnings at $10.83 EPS.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The business had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. During the same quarter in the previous year, the firm posted $2.30 earnings per share. The company's revenue for the quarter was down 4.2% on a year-over-year basis.

Several other research analysts also recently weighed in on BIO. Wall Street Zen downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday. Citigroup reduced their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company reduced their price objective on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating for the company in a research note on Monday. UBS Group reduced their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Royal Bank of Canada dropped their price objective on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $324.25.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock traded up $1.51 during trading on Wednesday, hitting $231.70. The stock had a trading volume of 165,459 shares, compared to its average volume of 327,165. The stock's 50 day moving average is $236.17 and its two-hundred day moving average is $283.58. Bio-Rad Laboratories has a 1 year low of $211.43 and a 1 year high of $387.99. The stock has a market cap of $6.31 billion, a price-to-earnings ratio of -3.56 and a beta of 0.93. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18.

Institutional Investors Weigh In On Bio-Rad Laboratories

A number of institutional investors and hedge funds have recently made changes to their positions in BIO. Venturi Wealth Management LLC increased its stake in Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after acquiring an additional 87 shares during the last quarter. GeoWealth Management LLC grew its holdings in shares of Bio-Rad Laboratories by 342.9% during the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after purchasing an additional 72 shares in the last quarter. Picton Mahoney Asset Management increased its position in shares of Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc purchased a new stake in Bio-Rad Laboratories in the fourth quarter valued at approximately $33,000. Finally, Cape Investment Advisory Inc. bought a new stake in Bio-Rad Laboratories during the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 65.24% of the company's stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.